Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SoftOx Solutions AS ( (DE:6FV) ) has issued an announcement.
SoftOx Solutions AS has announced a strategic shift in its clinical focus towards chronic lung diseases, particularly targeting cystic fibrosis, in its upcoming proof-of-concept trial. This change aims to establish the safety and efficacy of its SoftOx Inhalation Solution (SIS) and explore its potential in broader clinical applications. The company sees significant commercial potential in addressing unmet needs in chronic lung infections, with an estimated market size of over $600 million for cystic fibrosis and up to $5 billion for non-cystic fibrosis bronchiectasis. The trial, set to begin in Q1 2026, will not affect previously announced budgets and timelines, and SoftOx anticipates that positive results could attract partnerships with global pharmaceutical companies.
More about SoftOx Solutions AS
SoftOx Solutions AS is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. It focuses on developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi, leveraging extensive research and development in collaboration with leading Nordic research institutes.
YTD Price Performance: 685.71%
Average Trading Volume: 21,428,568
Current Market Cap: NOK248.1M
Learn more about 6FV stock on TipRanks’ Stock Analysis page.